Clinical improvement (reduced inflammation, stable organ function) is reported in approximately 65–70% of treated cohorts in early trials. However, 'success' varies by metric—some patients show antibody titre reduction, others primarily symptomatic relief. Remission induction (complete drug-free resolution) remains rare; most benefit takes the form of reduced relapse frequency or lower maintenance steroid doses over 12–24 months.
Registered trial data spans phase I safety through phase II efficacy work across global centres. Representative studies report disease activity index improvements in 60–75% of infused cohorts over 12 months, with renal histology stabilisation in 40–55% of lupus nephritis cases. Cytokine profiling shows durable reduction in pro-inflammatory markers (TNF-α, IL-6) persisting 6–9 months post-infusion. No completed phase III pivotal trial has yet reported, making this investigational rather than standard-of-care.
האם אני מועמד? → · Lupus (SLE): full overview → · עלות זאבת (SLE) → · Cost →
בדוקה רפואית על ידי צוות העריכה של StemCellAtlas עם Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) של קליניקת השותף Stem Plus (סופיה), כנגד הנחיות ISSCR, FDA ו-EMA. Educational information, not medical advice; figures indicative.
רפואה רגנרטיבית מאושרת GMP בלב האיחוד האירופי — החל מ-3,000–8,000 יורו, חלק קטן ממחירי ארהב או גרמניה. פרוטוקולים מותאמים אישית למטופלים מ-50+ מדינות.
בדיקה רפואית חינם